Needham & Company LLC Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

06 Mar 2026, 08:38 by Scott Moore · The Cerbat Gem

Cooper Companies (NASDAQ:COO – Get Free Report) had its price objective hoisted by investment analysts at Needham & Company LLC from $99.00 to $101.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 25.94% from the stock’s previous close.

Several other research analysts have also weighed in on COO. Stifel Nicolaus set a $95.00 price target on shares of Cooper Companies and gave the company a “buy” rating in a research report on Friday, December 5th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. William Blair raised Cooper Companies to a “strong-buy” rating in a research report on Friday, January 30th. Mizuho set a $100.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. Finally, Barclays set a $98.00 price objective on Cooper Companies and gave the company an “overweight” rating in a research note on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $90.50.

Get Our Latest Report on Cooper Companies

Cooper Companies Price Performance

COO stock opened at $80.20 on Friday. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $91.59. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The stock has a market cap of $15.65 billion, a price-to-earnings ratio of 42.66, a price-to-earnings-growth ratio of 2.34 and a beta of 1.02. The business has a fifty day moving average of $82.23 and a two-hundred day moving average of $75.95.

Cooper Companies (NASDAQ:COO – Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.07. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, research analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

Insider Transactions at Cooper Companies

In other news, CEO Albert G. White III acquired 10,000 shares of Cooper Companies stock in a transaction dated Tuesday, December 16th. The shares were acquired at an average cost of $80.80 per share, for a total transaction of $808,000.00. Following the acquisition, the chief executive officer owned 236,151 shares of the company’s stock, valued at $19,081,000.80. This trade represents a 4.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lawrence Erik Kurzius bought 2,000 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were purchased at an average price of $82.50 per share, with a total value of $165,000.00. Following the purchase, the director owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 16,014 shares of company stock valued at $1,304,416 over the last quarter. Insiders own 2.08% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. New York Life Investment Management LLC raised its position in shares of Cooper Companies by 0.6% during the 4th quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock worth $2,241,000 after acquiring an additional 158 shares in the last quarter. Root Financial Partners LLC raised its holdings in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares in the last quarter. Allworth Financial LP lifted its position in shares of Cooper Companies by 14.1% during the 4th quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock worth $111,000 after buying an additional 167 shares during the last quarter. Wealth Alliance LLC boosted its holdings in shares of Cooper Companies by 4.2% in the 2nd quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after buying an additional 171 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. raised its stake in Cooper Companies by 1.3% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock worth $961,000 after acquiring an additional 175 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Company raised full‑year 2026 EPS and free‑cash‑flow guidance, citing strong momentum for MyDay and MiSight contact‑lens franchises — a clear upside catalyst for revenue and cash generation expectations. Article Title
Positive Sentiment: Q1 results beat EPS estimates: reported $1.10 EPS vs. ~ $1.03 consensus; revenue roughly $1.02B (+6.2% YoY) with improved margins and stronger operating cash flow — supports the raised guidance. Press Release
Positive Sentiment: Product/clinical momentum: CooperVision highlighted research at NCC 2026 supporting long‑term comfort and wear for contact lenses — bolsters competitive positioning for MyDay/MiSight adoption. PR
Positive Sentiment: Insider buying activity flagged by data services (multiple recent insider purchases) — can be read as management confidence in outlook. QuiverQuant
Neutral Sentiment: Full earnings call transcript and slide deck released — useful for investors who want line‑by‑line detail on regional trends, product growth and cadence of guidance. Transcript
Neutral Sentiment: Investing press pieces highlight a strategic‑review focus at the company — could signal future capital allocation or portfolio moves but timing/impact are uncertain. Investing.com
Negative Sentiment: Rothschild & Co Redburn downgraded COO from Buy to Neutral with an $85 price target — an analyst downgrade that can pressure the stock despite the outlook upgrade. Finviz

Cooper Companies Company Profile

(Get Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.